Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (VECTITAX)
Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer
Sponsor: Amgen
Listed as NCT01264328, this PHASE2 trial focuses on Head and Neck Cancer and remains completed. Sponsored by Amgen, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — May 2019 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Trial Form Support S.L.
For direct contact, visit the study record on ClinicalTrials.gov .